-
Je něco špatně v tomto záznamu ?
Effect of antidiabetic treatment on bone
P. Jackuliak, M. Kužma, J. Payer
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, přehledy
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- diabetes mellitus 2. typu komplikace farmakoterapie MeSH
- hypoglykemika škodlivé účinky MeSH
- inhibitory kostní resorpce terapeutické užití MeSH
- inkretiny farmakologie MeSH
- inzulin farmakologie MeSH
- kosti a kostní tkáň účinky léků MeSH
- lidé MeSH
- metformin farmakologie MeSH
- osteoporóza komplikace diagnóza farmakoterapie MeSH
- sulfonylmočovinové sloučeniny škodlivé účinky MeSH
- thiazolidindiony škodlivé účinky MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Patients with diabetes mellitus are at an increased risk of bone fractures. Several groups of effective antidiabetic drugs are available, which are very often given in combination. The effects of these medications on bone metabolism and fracture risk must not be neglected. Commonly used antidiabetic drugs might have a positive, neutral or negative impact on skeletal health. Increased risk of fracture has been identified with use of thiazolidinediones, most definitively in women. Also treatment with sulfonylureas can have adverse effects on bone. One consequence of these findings has been greater attention to fracture outcomes in trails of new diabetes medication (incretins and SGLT-2 inhibitors). The effect of insulin on bone is discussed and the risk of fractures in patients using insulin seems to be unrelated to insulin as itself. The aim of the review is to summarize effects of antidiabetic treatment on bone - bone mineral density, fractures and bone turnover markers. The authors also try to recommend a strategy how to treat patients with diabetes mellitus regarding the risk of osteoporotic fractures. In this review the problem of how to treat osteoporosis in patient with diabetes is also discussed.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21028177
- 003
- CZ-PrNML
- 005
- 20220325110101.0
- 007
- ta
- 008
- 211105s2019 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934297 $2 doi
- 035 __
- $a (PubMed)31842574
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Jackuliak, Peter, $d 1981- $7 xx0227317 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 245 10
- $a Effect of antidiabetic treatment on bone / $c P. Jackuliak, M. Kužma, J. Payer
- 504 __
- $a Literatura
- 520 9_
- $a Patients with diabetes mellitus are at an increased risk of bone fractures. Several groups of effective antidiabetic drugs are available, which are very often given in combination. The effects of these medications on bone metabolism and fracture risk must not be neglected. Commonly used antidiabetic drugs might have a positive, neutral or negative impact on skeletal health. Increased risk of fracture has been identified with use of thiazolidinediones, most definitively in women. Also treatment with sulfonylureas can have adverse effects on bone. One consequence of these findings has been greater attention to fracture outcomes in trails of new diabetes medication (incretins and SGLT-2 inhibitors). The effect of insulin on bone is discussed and the risk of fractures in patients using insulin seems to be unrelated to insulin as itself. The aim of the review is to summarize effects of antidiabetic treatment on bone - bone mineral density, fractures and bone turnover markers. The authors also try to recommend a strategy how to treat patients with diabetes mellitus regarding the risk of osteoporotic fractures. In this review the problem of how to treat osteoporosis in patient with diabetes is also discussed.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a inhibitory kostní resorpce $x terapeutické užití $7 D050071
- 650 _2
- $a kosti a kostní tkáň $x účinky léků $7 D001842
- 650 _2
- $a diabetes mellitus 2. typu $x komplikace $x farmakoterapie $7 D003924
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypoglykemika $x škodlivé účinky $7 D007004
- 650 _2
- $a inkretiny $x farmakologie $7 D054795
- 650 _2
- $a inzulin $x farmakologie $7 D007328
- 650 _2
- $a metformin $x farmakologie $7 D008687
- 650 _2
- $a osteoporóza $x komplikace $x diagnóza $x farmakoterapie $7 D010024
- 650 _2
- $a sulfonylmočovinové sloučeniny $x škodlivé účinky $7 D013453
- 650 _2
- $a thiazolidindiony $x škodlivé účinky $7 D045162
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kužma, Martin $7 xx0227382 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 700 1_
- $a Payer, Juraj, $d 1958- $7 xx0140923 $u 5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 68, Suppl 2 (2019), s. S107-S120
- 773 0_
- $t Advances in internal medicine $g (2019), s. S107-S120 $w MED00208905
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31842574 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20211105 $b ABA008
- 991 __
- $a 20220325110053 $b ABA008
- 999 __
- $a ok $b bmc $g 1728779 $s 1148722
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 68 $c Suppl 2 $d S107-S120 $e 20191130 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- BMC __
- $a 2019 $d S107-S120 $m Advances in internal medicine $x MED00208905
- LZP __
- $b NLK118 $a Pubmed-20211105